SAFETY DATA SHEET

Orbifloxacin / Posaconazole / Mometasone Formulation

Version 4.6  Revision Date: 27.08.2021  SDS Number: 439121-00013  Date of last issue: 04.01.2021

Date of first issue: 06.01.2016

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Orbifloxacin / Posaconazole / Mometasone Formulation

Manufacturer or supplier’s details
Company name of supplier: MSD
Address: 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Eye irritation: Category 2B
Reproductive toxicity: Category 1B

GHS label elements
Hazard pictograms:

Signal Word: Danger

Hazard Statements:
H320 Causes eye irritation.
H360DF May damage the unborn child. Suspected of damaging fertility.

Precautionary Statements:
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P337 + P313 IF eye irritation persists: Get medical advice/ attention.

Storage:
SAFETY DATA SHEET

Orbifloxacin / Posaconazole / Mometasone
Formulation

Version 4.6  Revision Date: 27.08.2021  SDS Number: 439121-00013  Date of last issue: 04.01.2021  Date of first issue: 06.01.2016

P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>White mineral oil (petroleum)</td>
<td>8042-47-5</td>
<td>&gt;= 50 -&lt; 70</td>
</tr>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>&gt;= 1 -&lt; 5</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>171228-49-2</td>
<td>&gt;= 0.1 -&lt; 1</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>&gt;= 0.1 -&lt; 1</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air. Get medical attention.
In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Causes eye irritation. May damage the unborn child. Suspected of damaging fertility.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES
SAFETY DATA SHEET

Orbifloxacin / Posaconazole / Mometasone Formulation

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire fighting:
Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters:
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
If sufficient ventilation is unavailable, use with local exhaust
Advice on safe handling: Do not get on skin or clothing. Do not breathe vapors or spray mist. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labeled containers. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>White mineral oil (petroleum)</td>
<td>8042-47-5</td>
<td>VLE-PPT (Mist)</td>
<td>5 mg/m³</td>
<td>NOM-010-STPS-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>5 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>TWA</td>
<td>0.2 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>171228-49-2</td>
<td>TWA</td>
<td>300 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin

| Wipe limit | 10 µg/100 cm² | Internal |
SAFETY DATA SHEET

Orbifloxacin / Posaconazole / Mometasone Formulation

Engineering measures: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Combined particulates and organic vapor type

Hand protection: Chemical-resistant gloves

Remarks: Consider double gloving.

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: suspension

Color: white to off-white

Odor: odorless

Odor Threshold: No data available

pH: No data available

Melting point/freezing point: No data available

Initial boiling point and boiling range: No data available

Flash point: No data available

Evaporation rate: No data available
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td></td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
<tr>
<td>Particle size</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

### SECTION 10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity</td>
<td>Not classified as a reactivity hazard.</td>
</tr>
<tr>
<td>Chemical stability</td>
<td>Stable under normal conditions.</td>
</tr>
<tr>
<td>Possibility of hazardous reactions</td>
<td>Can react with strong oxidizing agents.</td>
</tr>
<tr>
<td>Conditions to avoid</td>
<td>None known.</td>
</tr>
<tr>
<td>Incompatible materials</td>
<td>Oxidizing agents</td>
</tr>
<tr>
<td>Hazardous decomposition products</td>
<td>No hazardous decomposition products are known.</td>
</tr>
</tbody>
</table>
SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
Remarks: No significant adverse effects were reported
No mortality observed at this dose.

Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg
Remarks: No significant adverse effects were reported

Components:
White mineral oil (petroleum):
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Orbifloxacin:
Acute oral toxicity: LD50 (Rat): > 3,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Mouse): > 2,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Dog): > 600 mg/kg
Symptoms: Vomiting
Remarks: No mortality observed at this dose.

Acute inhalation toxicity: Remarks: No data available

Acute dermal toxicity: Remarks: No data available

Acute toxicity (other routes of administration): LD50 (Rat): > 200 mg/kg
Application Route: Intramuscular
LD50 (Mouse): 500 mg/kg  
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg  
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg  
Application Route: Intravenous

**Posaconazole:**

Acute oral toxicity  
LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 3,000 mg/kg

Acute dermal toxicity  
LD50 (Rat): > 2,000 mg/kg

**Mometasone:**

Acute oral toxicity  
LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity  
LC50 (Rat): > 3.3 mg/l  
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l  
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration)  
LD50 (Rat): 300 mg/kg  
Application Route: Subcutaneous  
Symptoms: Breathing difficulties

**Skin corrosion/irritation**

Not classified based on available information.

**Product:**

Species  
Rabbit

Result  
Mild skin irritation

**Components:**

**White mineral oil (petroleum):**

Species  
Rabbit

Result  
No skin irritation

**Orbifloxacin:**

Species  
Rabbit

Method  
Draize Test
Result: No skin irritation

**Posaconazole:**
Species: Rabbit
Result: No skin irritation

**Mometasone:**
Species: Rabbit
Result: No skin irritation

**Serious eye damage/eye irritation**
Causes eye irritation.

**Product:**
Species: Rabbit
Result: Mild eye irritation

**Components:**
**White mineral oil (petroleum):**
Species: Rabbit
Result: No eye irritation

**Orbifloxacin:**
Species: Rabbit
Result: Mild eye irritation
Method: Draize Test

**Posaconazole:**
Species: Rabbit
Result: Mild eye irritation

**Mometasone:**
Species: Rabbit
Result: No eye irritation

**Respiratory or skin sensitization**

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
Not classified based on available information.

**Product:**
Test Type: Magnusson-Kligman-Test
Routes of exposure: Dermal
Result: Not a skin sensitizer.
Components:

White mineral oil (petroleum):
Test Type: Buehler Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

Orbifloxacin:
Test Type: Maximization Test
Routes of exposure: Dermal
Species: Guinea pig
Result: Not a skin sensitizer.

Posaconazole:
Test Type: Magnusson-Kligman-Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

Mometasone:
Test Type: Maximization Test
Routes of exposure: Dermal
Species: Guinea pig
Assessment: Does not cause skin sensitization.
Result: negative
Remarks: The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

White mineral oil (petroleum):
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials

Orbifloxacin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: equivocal
## Genotoxicity in vivo

**Orbifloxacin / Posaconazole / Mometasone Formulation**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse Lymphoma</td>
<td>positive</td>
</tr>
<tr>
<td>Chromosomal aberration</td>
<td>positive</td>
</tr>
</tbody>
</table>

**Genotoxicity in vivo**

- **Test Type:** Micronucleus test  
  - **Species:** Mouse  
  - **Cell type:** Bone marrow  
  - **Application Route:** Intraperitoneal injection  
  - **Result:** negative

- **Test Type:** unscheduled DNA synthesis assay  
  - **Species:** Rat  
  - **Cell type:** Liver cells  
  - **Application Route:** Oral  
  - **Result:** negative

**Germ cell mutagenicity - Assessment**

- Weight of evidence does not support classification as a germ cell mutagen.

### Posaconazole:

**Genotoxicity in vitro**

- **Test Type:** Bacterial reverse mutation assay (AMES)  
  - **Result:** negative

- **Test Type:** Chromosomal aberration  
  - **Result:** negative

**Genotoxicity in vivo**

- **Test Type:** Micronucleus test  
  - **Species:** Mouse  
  - **Cell type:** Bone marrow  
  - **Application Route:** Intravenous  
  - **Result:** negative

### Mometasone:

**Genotoxicity in vitro**

- **Test Type:** Bacterial reverse mutation assay (AMES)  
  - **Result:** negative

- **Test Type:** Chromosomal aberration  
  - **Test system:** Chinese hamster lung cells  
  - **Result:** negative

- **Test Type:** Chromosomal aberration  
  - **Test system:** Chinese hamster ovary cells  
  - **Result:** positive

- **Test Type:** Mouse Lymphoma  
  - **Result:** negative

**Genotoxicity in vivo**

- **Test Type:** Micronucleus test  
  - **Species:** Mouse
Application Route: Oral  
Result: negative

Test Type: Chromosomal aberration  
Species: Rat  
Cell type: Bone marrow  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Result: negative

Germ cell mutagenicity - Assessment: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Components:
White mineral oil (petroleum):
Species: Rat  
Application Route: Ingestion  
Exposure time: 24 Months  
Result: negative

Orbifloxacin:
Species: Rat  
Application Route: Oral  
Exposure time: 2 Years  
NOAEL: 200 mg/kg body weight  
Result: negative

Species: Mouse  
Application Route: Oral  
Exposure time: 2 Years  
NOAEL: 200 mg/kg body weight  
Result: negative

Remarks: The mechanism or mode of action is not relevant in humans.

Posaconazole:
Species: Rat  
Application Route: oral (feed)  
Exposure time: 2 Years  
Result: positive  
Remarks: The mechanism or mode of action is not relevant in humans.

Species: Mouse  
Application Route: Oral  
Exposure time: 2 Years  
Result: positive  
Remarks: The mechanism or mode of action is not relevant in humans.
Mometasone:
Species: Rat
Application Route: Inhalation
Exposure time: 2 Years
Dose: 0.067 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Inhalation
Exposure time: 19 Months
Dose: 0.160 mg/kg body weight
Result: negative

Reproductive toxicity
May damage the unborn child. Suspected of damaging fertility.

Components:

White mineral oil (petroleum):
Effects on fertility:
Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Skin contact
Result: negative

Effects on fetal development:
Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

Orbifloxacin:
Effects on fertility:
Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity Parent: NOAEL: 50 mg/kg body weight
Early Embryonic Development: NOAEL: 50 mg/kg body weight
Result: No adverse effects.

Effects on fetal development:
Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Embryo-fetal toxicity.: LOAEL: 333 mg/kg body weight
Result: No teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 20 mg/kg body weight
Embryo-fetal toxicity.: NOAEL: 60 mg/kg body weight
Result: No effects on early embryonic development., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain.

Test Type: Development
Species: Dog
Application Route: Oral
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
Result: Effects on postnatal development., Skeletal malformations.

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

Posaconazole:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat, male
General Toxicity Parent: NOAEL: 180 mg/kg body weight
Symptoms: No effects on mating performance.
Result: negative

Test Type: Fertility/early embryonic development
Species: Rat, female
General Toxicity Parent: NOAEL: 45 mg/kg body weight
Symptoms: No effects on mating performance.
Result: negative

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat, female
Application Route: Oral
Developmental Toxicity: LOAEL: 29 mg/kg body weight
Result: Fetotoxicity., Malformations were observed.

Test Type: Embryo-fetal development
Species: Rabbit, female
Developmental Toxicity: LOAEL: 40 mg/kg body weight
Result: Fetotoxicity.

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

Mometasone:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0.015 mg/kg body weight
Symptoms: Reduced embryonic survival, Reduced fetal weight.
Result: No effects on fertility., Effect on reproduction capacity.

Effects on fetal development: Test Type: Embryo-fetal development
Species: Mouse
Application Route: Subcutaneous
Embryo-fetal toxicity: LOAEL: 0.06 mg/kg body weight
Result: Embryotoxic effects, Teratogenicity and developmental toxicity

Test Type: Embryo-fetal development
Species: Rat
Application Route: Dermal
Embryo-fetal toxicity: LOAEL: 0.3 mg/kg body weight
Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Dermal
Embryo-fetal toxicity: LOAEL: 0.15 mg/kg body weight
Result: Embryo-fetal toxicity, Malformations were observed.

Test Type: Embryo-fetal development
Species: Rat
Application Route: Subcutaneous
Embryo-fetal toxicity: LOAEL: 0.15 mg/kg body weight
Result: Effects on newborn.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Embryo-fetal toxicity: LOAEL: 0.7 mg/kg body weight
Result: Embryo-fetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments, Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure
Not classified based on available information.

Components:

Mometasone:

Remarks: Based on available data, the classification criteria are not met.

STOT-repeated exposure
Not classified based on available information.

Components:

Posaconazole:

Routes of exposure: Ingestion
Target Organs: Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.
Mometasone:
Routes of exposure: inhalation (dust/mist/fume)
Target Organs: Immune system, Liver, Kidney, Skin
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

White mineral oil (petroleum):
Species: Rat
LOAEL: 160 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Species: Rat
LOAEL: >= 1 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 4 Weeks
Method: OECD Test Guideline 412

Orbifloxacin:
Species: Rat
NOAEL: 20 mg/kg
LOAEL: 80 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: Testis, Liver, Kidney, spleen

Species: Mouse
NOAEL: 80 mg/kg
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 3 Months

Species: Juvenile dog
NOAEL: 50 mg/kg
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 14 Days
Target Organs: Heart, Bone
Symptoms: Gastrointestinal disturbance
Remarks: mortality observed

Species: Juvenile dog
NOAEL: 2 mg/kg
LOAEL: 3 mg/kg
Application Route: Oral
Exposure time: 90 Days
Target Organs: Bone
SAFETY DATA SHEET

Orbifloxacin / Posaconazole / Mometasone Formulation

Version 4.6  Revision Date: 27.08.2021  SDS Number: 439121-00013  Date of last issue: 04.01.2021
Date of first issue: 06.01.2016

Remarks

No significant adverse effects were reported

Species: Dog
NOAEL: 37.5 mg/kg
Application Route: Oral
Exposure time: 30 Days

Species: Cat
NOAEL: 7.5 mg/kg
LOAEL: 22.5 mg/kg
Application Route: Oral
Exposure time: 1 Months
Symptoms: Gastrointestinal disturbance

Posaconazole:

Species: Rat, female
LOAEL: 5 mg/kg
Application Route: Oral
Exposure time: 6 Months
Target Organs: Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species: Dog
LOAEL: 3 mg/kg
Application Route: Oral
Exposure time: 392 Days
Target Organs: Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue

Species: Monkey
LOAEL: 15 mg/kg
Application Route: Oral
Exposure time: 1 Months
Target Organs: Bone marrow, Adrenal gland, Lymph nodes, Blood

Species: Dog
LOAEL: 3 mg/kg
Application Route: Oral
Exposure time: 56 Weeks
Target Organs: Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue

Species: Monkey
LOAEL: 180 mg/kg
Application Route: Oral
Exposure time: 12 Months
Target Organs: Blood, Gastrointestinal tract, spleen

Species: Monkey
LOAEL: 8 mg/kg
Application Route: Intravenous
Exposure time: 1 Months
Target Organs: Cardio-vascular system, Lungs, Adrenal gland, Blood
Mometasone:
Species: Rat
NOAEL: 0.005 mg/kg
LOAEL: 0.3 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Dog
LOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Rat
NOAEL: 0.00013 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species: Dog
NOAEL: 0.0005 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.

Components:
Mometasone:
Not applicable

Experience with human exposure

Components:
Orbifloxacin:
Ingestion: Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash
Remarks: May cause photosensitization.

Posaconazole:
Ingestion: Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhea, hypertension, neutropenia, electrolyte imbalance

Mometasone:
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain,
musculoskeletal pain, immune system effects, indigestion

Skin contact: Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:
Remarks: Dermal absorption possible

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

White mineral oil (petroleum):

Toxicity to fish: LC50 (Onchorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Posaconazole:

Toxicity to fish: NOEC (Onchorhynchus mykiss (rainbow trout)): 1,000 mg/l
Exposure time: 28 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 1,000 mg/l
Exposure time: 21 d

Toxicity to fish (Chronic toxicity): NOEC (Onchorhynchus mykiss (rainbow trout)): 1,000 mg/l
Exposure time: 28 d

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.276 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity):

NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

NOEC (Daphnia magna (Water flea)): 0.244 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms:

EC50 (Natural microorganism): > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Mometasone:

Toxicity to fish:

LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates:

EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants:

EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity):

NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

NOEC (Daphnia magna (Water flea)): 0.34 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.
Toxicity to microorganisms:
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

Persistence and degradability

Components:
White mineral oil (petroleum):
Biodegradability
Result: Not readily biodegradable.
Biodegradation: 31 %
Exposure time: 28 d

Posaconazole:
Biodegradability
Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 h
Method: OECD Test Guideline 314

Stability in water
Degradation half life (DT50): > 30 d
Method: OECD Test Guideline 111

Mometasone:
Biodegradability
Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water
Hydrolysis: 50 %(12 d)
Method: OECD Test Guideline 111

Bioaccumulative potential

Components:
Posaconazole:
Bioaccumulation
Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 20
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water
log Pow: 4.15

Mometasone:
SAFETY DATA SHEET
Orbifloxacin / Posaconazole / Mometasone Formulation

Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 4.68

Mobility in soil

Components:

Posaconazole:
Distribution among environmental compartments: log Koc: 5.52

Mometasone:
Distribution among environmental compartments: log Koc: 4.02

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)
Class: 9
Packing group: III
Labels: 9

IATA-DGR
UN/ID No.: UN 3082
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (Mometasone, Posaconazole)
Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 964
Packing instruction (passenger aircraft): 964
Environmentally hazardous: yes
SAFETY DATA SHEET

Orbifloxacin / Posaconazole / Mometasone
Formulation

Version 4.6  Revision Date: 27.08.2021  SDS Number: 439121-00013  Date of last issue: 04.01.2021  Date of first issue: 06.01.2016

IMDG-Code
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)

Class : 9
Packing group : III
Labels : 9

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills. : Not applicable

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
### SAFETY DATA SHEET

**Orbifloxacin / Posaconazole / Mometasone Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.6</td>
<td>27.08.2021</td>
<td>439121-00013</td>
<td>04.01.2021</td>
<td>06.01.2016</td>
</tr>
</tbody>
</table>

**NOM-010-STPS-2014**

- **M**: Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting the Work Environment - Identification, Assessment and Control - Appendix 1 Occupational Exposure Limits

**ACGIH / TWA**

- 8-hour, time-weighted average

**NOM-010-STPS-2014 / VLE-PPT**

- Time weighted average limit value

**Sources of key data used to compile the Material Safety Data Sheet**


**Revision Date**

- 27.08.2021

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

**MX / Z8**